https://www.selleckchem.com/products/cddo-im.html
7 units/day (95% CI, 8.2 to 11.2 units; P 0.001) with aspart 70/30. The most common adverse events were gastrointestinal adverse effects in the exenatide group [nausea (21%), vomiting (16%), diarrhea (13%)]. The incidence of hypoglycaemia was similar in two groups (27% for exenatide and 38% for aspart 70/30, respectively; P = 0.1). In premixed human insulin-treated type 2 diabetic patients with inadequate glycaemic control, switching to exenatide BID plus glargine was superior to aspart 70/30 BID for glycaemic and weight control. I
Like
Comment
Share
